-
公开(公告)号:US20230008089A1
公开(公告)日:2023-01-12
申请号:US17939707
申请日:2022-09-07
IPC分类号: A61K35/768 , A61K45/06 , C12N7/00
摘要: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:US20220133825A1
公开(公告)日:2022-05-05
申请号:US17574763
申请日:2022-01-13
IPC分类号: A61K35/768 , C07K14/47 , A61K9/00 , C07K14/16 , C12N9/10 , C07K14/07 , C12N9/16 , A61P35/00 , C12N15/62 , C07K16/28
摘要: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:US11253559B2
公开(公告)日:2022-02-22
申请号:US16252338
申请日:2019-01-18
IPC分类号: A61K35/768 , A61P35/00 , A61K9/00 , C07K14/07 , C07K14/16 , C07K14/47 , C12N15/62 , C12N9/16 , C12N9/10 , C12N1/10 , C07K16/28
摘要: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:US20160235793A1
公开(公告)日:2016-08-18
申请号:US15048698
申请日:2016-02-19
IPC分类号: A61K35/768 , A61K45/06 , C12N7/00
CPC分类号: A61K35/768 , A61K39/12 , A61K45/06 , A61K2039/5256 , A61K2039/572 , A61K2039/575 , A61K2039/585 , C12N7/00 , C12N2710/24121 , C12N2710/24122 , C12N2710/24132 , C12N2710/24134 , C12N2710/24171
摘要: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
摘要翻译: 本发明涉及已被修饰以促进抗肿瘤免疫和/或降低针对病毒的宿主免疫和/或抗体应答的溶瘤性痘苗病毒。 至少部分地基于发现具有降低T细胞免疫的基因(白细胞介素-18结合蛋白)的基因组缺失的溶血性痘苗病毒(i); (ii)用相信会降低TLR2活化并因此降低抗体应答的唾液酸酶处理; (iii)携带增强细胞毒性T淋巴细胞诱导的基因(例如TRIF)和/或(iv)通过减少前列腺素E2降低肿瘤骨髓来源的抑制细胞减少肿瘤生长。 因此,本发明提供免疫酵解痘苗病毒及其用于治疗癌症的方法。
-
公开(公告)号:US11478518B2
公开(公告)日:2022-10-25
申请号:US15048698
申请日:2016-02-19
IPC分类号: A61K35/768 , A61K45/06 , C12N7/00 , A61K39/00
摘要: The present invention relates to oncolytic vaccinia viruses which have been modified to promote anti-tumor immunity and/or reduce host immunity and/or antibody response against the virus. It is based, at least in part, on the discovery that oncolytic vaccinia virus (i) bearing a genome deletion of a gene that reduces T cell immunity (interleukin-18 binding protein); (ii) treated with a sialidase enzyme which is believed to reduce TLR2 activation and therefore the antibody response; (iii) carrying a gene that enhances cytotoxic T lymphocyte induction (e.g., TRIF) and/or (iv) reduces tumor myeloid-derived suppressor cells by reducing prostaglandin E2 reduces tumor growth. Accordingly, the present invention provides for immunooncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:US20220133824A1
公开(公告)日:2022-05-05
申请号:US17574691
申请日:2022-01-13
IPC分类号: A61K35/768 , A61P35/00 , C12N9/16 , C07K14/16 , C12N9/10 , A61K9/00 , C07K14/07 , C12N15/62 , C07K14/47 , C07K16/28
摘要: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
公开(公告)号:US20190142883A1
公开(公告)日:2019-05-16
申请号:US16252338
申请日:2019-01-18
摘要: This disclosure relates to modified viruses, e.g., oncolytic vaccinia viruses, which have been modified to contain an exogenous nucleic acid that expresses a protein that modulates STAT3 activity. It is based, at least in part, on the discovery that vaccinia viruses modified to contain nucleic acid encoding PIAS3 and that express PIAS3 or a fragment thereof can inhibit STAT3 activity and enhance the anti-cancer activity of the vaccinia virus. Accordingly, this disclosure provides for oncolytic vaccinia viruses and methods of using them in the treatment of cancers.
-
-
-
-
-
-